According to 5 analysts, the average rating for Otonomy stock is Strong Buy. The 12-month stock price forecast is 5.63, which is an increase of 130.74% from the latest price. The 12-month stock price forecast is 5.63, which is an increase of 130.74% from the latest price Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has decreased by 13.7% and is now trading at $2.26. View which stocks have been most impacted by COVID-19 Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy.. Hearing, balance and connection—all easy to take for granted, but profoundly impactful when disrupted. Disorders of the ear are often associated with feelings of frustration, decreased social interaction and depression. At Otonomy, our focus is on making new treatments a reality for the millions living with the debilitating, daily impact of these. Founders Jay Lichter, Jeffrey Harris. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Otonomy, Inc. Stock Symbol NASDAQ:OTIC. Company Type For Profit. Contact Email email@example.com. Phone Number 8587687809. Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier.
Otonomy Inc. Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone. Furthermore, Otonomy Inc. (OTIC)'s beta value is 1.98, and its average true range (ATR) is 0.14. The company's stock has been forecasted to trade at an average price of $6.30 over the course of the next 52 weeks, with a low of $5.00 and a high of $9.00. Based on these price targets, the low is -114.59% off current price, whereas the price has to move -286.27% to reach the yearly target high. Additionally, analysts' median price of $6.00 is likely to be welcomed by investors. Otonomy Inc stock has gained 79.91% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver's proprietary ranking system, gives OTIC stock a score of 93 out of a possible 100. That rank is influenced by a short-term technical score of 97. OTIC's rank also includes a long-term technical score of 93. The fundamental score for OTIC is 89. In addition to the average rating from Wall Street analysts, OTIC stock has a mean target. On May 28, 2021, the Company entered into an asset purchase agreement with ALK-Abelló, Inc. ('ALK') pursuant to which ALK acquired the Company's intellectual property and other material assets with respect to the Company's product known as OTIPRIO ® (ciprofloxacin otic suspension). Under the agreement, ALK is obligated to pay the Company an upfront payment and certain amounts based on net sales of OTIPRIO for a specified period of time. Prior to the acquisition, ALK had bee Find real-time OTIC - Otonomy Inc stock quotes, company profile, news and forecasts from CNN Business
Otonomy Inc. (OTIC) saw an uptrend of 5.11% in the recent trading with $2.47 being its most recent. The current price level -64.63% lower than the highest price of $6.98 marked by the stock while trading over the past 52-weeks, whereas it is 15.42% higher than the lowest price of $2.14 the company dropped to over past 52-weeks Stock analysis for Otonomy Inc (OTIC:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile
Otonomy Inc (OTIC) stock has gained 12.26% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver's proprietary ranking system, gives OTIC stock a score of 31 out of a possible 100. That rank is mainly influenced by a long-term technical score of 1 View today's stock price, news and analysis for Otonomy Inc. (OTIC). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more The new note on the price target was released on December 24, 2019, representing the official price target for Otonomy Inc. stock. The Average True Range (ATR) for Otonomy Inc. is set at 0.62, with the Price to Sales ratio for OTIC stock in the period of the last 12 months amounting to 479.60
View Otonomy, Inc. OTIC investment & stock information. Get the latest Otonomy, Inc. OTIC detailed stock quotes, stock data, Real-Time ECN, charts, stats and more Get the latest Otonomy Inc (OTIC) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions A high-level overview of Otonomy, Inc. (OTIC) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools Otonomy Inc. [NASDAQ: OTIC] closed the trading session at $4.58 on 01/28/21. The day's price range saw the stock hit a low of $3.91, while the highest price level was $4.70. The company report on January 5, 2021 that Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
Find the latest Otonomy, Inc. (OTIC) stock quote, history, news and other vital information to help you with your stock trading and investing Otonomy Inc Stock , OTIC. 2.36 +0.01 +0.43% Official Close 6/15/2021 NAS. Add to watchlist Start Trading >> Plus500. 76.4% of retail CFD accounts lose money. News More News. Seeking. SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by. Otonomy Announces Pricing of $30.1 Million Public Offering. SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a. Looking to buy Otonomy stock? Get the stock price and latest news for OTIC and start trading today with zero commissions. Get Free Stock. OTIC. Otonomy — $0.00 (0.00%) Today. Small Market Cap. 1D 1W 1M 3M 6M 1Y 5Y. Embed . View Otonomy stock trends here About OTIC. Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firm.
Otonomy Inc Aktie (OTIC) mit Realtime-Aktienkurs, Chart, Bilanzinformationen, Dividenden, historischen Daten, aktuellen News und Analysen Find the latest Otonomy, Inc. (OTIC) stock discussions in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors Stock Common: OTONOMY INC: OTIC: Latest USPTO Trademark Filings . Mark Image. Registration | Serial. Trademark. Application Date OTIVIDEX 87429785. OTIVIDEX. 2017-04-28 OTIPRIO 5013864 86590273. OTIPRIO. 2015-04-07 PROAURIC 86206773. PROAURIC. 2014-02-27 AURIPRO 86206771. AURIPRO. 2014-02-27 OTONOMY 4293087 85435807. OTONOMY . 2011-09-29. USPTO Patent Activity . Patent Title. Patent. Otonomy Inc. (OTIC) saw an uptrend of 5.56% in the recent trading with $2.47 being its most recent. The current price level -64.63% lower than the highest price of $6.98 marked by the stock while trading over the past 52-weeks, whereas it is 22.89% higher than the lowest price of $2.01 the company dropped to over past 52-weeks Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firmâ€™s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO.
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of. Otonomy Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions Otonomy. stock was originally listed at a price of $17.15 in Aug 13, 2014. If you had invested in Otonomy stock at $17.15, your return over the last 6 years would have been -86.18%, for an annualized return of -28.1% All the business activity primarily operates through the region of U.S. Otonomy shares were trading up 14.15% at $3.63 on Tuesday. The stock has a 52-week high of $4.18 and a 52-week low of $1.53
View the latest OTIC stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of OTONOMY, INC. This page features the latest news about the Otonomy Inc share Investors in Otonomy, Inc.(OTIC Quick Quote OTIC - Free Report) need to pay close attention to the stock based on moves in the options market lately.That is because the Apr 16, 2021 $200.00 Call.
Get the latest news and real-time alerts from Otonomy, Inc. (OTIC) stock at Seeking Alpha Otonomy Inc. (NASDAQ: OTIC) is -63.52% lower on its value in year-to-date trading and has touched a low of $2.14 and a high of $6.98 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock Otonomy Inc. (NASDAQ: OTIC) stock closed at 2.35 per share at the end of the most recent trading day (a 0.86 % change compared to the prior day closing price) with a volume of 173.26K shares and market capitalization of 133.05M.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 56 people Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d) *The remainder of this cover page shall be filled out for a. Otonomy, Inc. (NASDAQ:OTIC) Director Jay Lichter sold 311,100 shares of Otonomy stock in a transaction that occurred on Thursday, February 25th. The shares were sold at an average price of $2.95, for a total transaction of $917,745.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this [
OTIC, Otonomy Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headline Investor Network: Otonomy, Inc. to Host Earnings Call • • ACCESSWIRE • Stocks • More OTONOMY INC. news... NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:30 PM Eastern Time . (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a price to the public of $2.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,111,110.
Otonomy, Inc. (OTIC) is making a move down in the market in today's trading session. The company, focused on the biotechnology space, is currently priced at $2.33 after tumbling -5.67% so far today. When it comes to biotechnology companies, there are quite a few aspects that have the potential to lead to movement in the market Otonomy Inc. (NASDAQ:OTIC) went down by -10.69% from its latest closing price compared to the recent 1-year high of $6.98. The company's stock price has collected -11.90% of loss in the last five trading sessions. Press Release reported on 02/25/21 that Otonomy to Participate in Three Upcoming Investor Conferences. Get the hottest stocks to trade every day before the market opens 100% free Otonomy, Inc. (NASDAQ:OTIC) trade information. In the face of being in the red during last session for losing -1.69%, in the last five days OTIC remained trading in the green while hitting it's week-highest on Monday, May 24 when the stock touched $2.50-6 price level, adding 6.8% to its value on the day Otonomy, Inc. (NASDAQ:OTIC) Stock: Performance and Outlook. In the latest trading session, 1,672,360 Otonomy, Inc. (NASDAQ:OTIC) shares changed hands as the company's beta touched 2.07. With the company's most recent per share price at $2.58 changing hands around $0.09 or 0.04% at last look, the market valuation stands at $123.7 Million Otonomy, Inc. (OTIC) is trending up in the market today. The company, one that is focused in the biotechnology sector, is presently priced at $2.56 after climbing 4.92% so far today. As it relates to biotech companies, there are a number of aspects that have the potential to lead to price movement in the market
On February 11, Otonomy will be reporting latest earnings. Wall Street analysts expect Otonomy will be reporting losses per share of $0.210. Go here to watch Otonomy stock price in real-time on. The Otonomy stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $2.34 and $2.30. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, May 21, 2021, and so far it has fallen -9.72%. Further fall is. 3 Wall Street analysts have issued ratings and price targets for Otonomy in the last 12 months. Their average twelve-month price target is $8.38, predicting that the stock has a possible upside of 254.87%. The high price target for OTIC is $11.00 and the low price target for OTIC is $5.50. There are currently 3 buy ratings for the stock. . ( OTIC ) including financial statements, level 2 data, and the latest Biotechnology news, research, and investment community discussio Otonomy Inc Annual Shareholders Meeting. 適時開示 その他. Otonomy Reports First Quarter 2021 Financial Results. Otonomy Announces Top-Line Results For The Phase 3 Clinical Trial Of Otividex.
Otonomy stock price target cut to $30 from $42 at J.P. Morgan MarketWatch. Friday, October 03, 2014. 06:00 AM ET. Almost half of venture-backed IPOs this year are losers MarketWatch. Monday, September 15, 2014. 12:58 PM ET. Where (in the Human Body) Venture Capital Is Going The Wall Street Journal Interactive Edition. More . Company Releases for Otonomy Inc. Tuesday, June 15, 2021. 08:07 AM ET. Otonomy Inc OTIC Morningstar Rating Rating as of Jun 18, 2021. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership.
Recent Stock Performance. 52-week high: $6.98. Company's 52-week low was at $2.05 . Price action over last quarter: down 59.92%. Company Profile. Otonomy Inc is a biopharmaceutical company. Otonomy Inc (NQ: OTIC ) 2.335 USD +0.005 (+0.21%) Streaming Delayed Price Updated: 12:35 PM EDT, Jun 1, 2021 Add to My Watchlist. Quote . Overview. Stock analysis for Otonomy Inc (7OT:Frankfurt) including stock price, stock chart, company news, key statistics, fundamentals and company profile
Get the latest stock price for Otonomy Inc. (OTIC:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings. We value your privacy. We and our partners store and/or access information on a device, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for personalised ads and content, ad and content. Get the latest Otonomy Inc (OTIC) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Finance. Sign in. Finance. finance_mode. Home. Watchlists. add. Create Watchlist. Most Active. Colony Capital Inc-1.99%. Nielsen Holdings PLC-0.95%. BCE Inc-0.49%. Mitsubishi UFJ Financial Group Inc +1.21%. PPD Inc. NASDAQ › Otonomy Inc aktienkurs › Otonomy. Börsenkurse; Charts; Orderbuch; Trades; News; Finanzwerte; Historisch; Zusammenfassung; Data Download; OTIC Otonomy Historische Daten . OTIC abonnieren. Kaufen. Verkaufen. Best deals to access real time data! Real-time Level 1 for Canada + USA. Monthly Subscription. for only. 32,99 € Free trial. Trade Alert US. Monthly Subscription. for only. Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock with the most powerful seasonal trend this week Perform Advanced Searches . For Dividend Stocks, Blue Chip Stocks, Most Active Stocks, Most Shorted Stocks, Cheap.
* OTONOMY INC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 14.5 MILLION SHARES OF COMMON STOCK AT PRICE TO PUBLIC OF $3.25 PER SHARE Source text for Eikon: Further company coverage: BRIEF-Otonomy. Otonomy (OTIC) share price, charts, trades & the UK's most popular discussion forums. Free forex prices, toplists, indices and lots more. Free forex prices, toplists, indices and lots more. 18/06/2021 11:22:22 +44 (0) 203 8794 460 Free Membership Logi View the real-time OTIC price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Otonomy against related stocks people have also bought
Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California. Stock Price Prediction: Update at 5:00pm EST: If tomorrow: Open lower Open higher High: 2.423 - 2.435 2.435 - 2.446 Low: 2.306 - 2.32 2.32 - 2.335 Close: 2.343 - 2.366 2.366 - 2.389 Technical analysis: as of: 2021-05-31 10:05:40 AM: Overall: Stoxline posted a NEUTRAL today, same as yesterday. Current trend. Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products. Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares. SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC. Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of.
Australian finance news, stock quotes, currency information and blogs . Back. Otonomy, Inc. (OTIC) Add to watchlist. NasdaqGS - NasdaqGS Real-time price. Currency in USD. 2.3750 +0.0150 (+0.64%) As of 02:36PM EDT. Market open. Loading interactive chart Recently Viewed. Your list is empty. Cryptocurrencies. Symbol Last price. Otonomy stock loses half its value after disappointing trial results of vertigo treatment. 02/22 08:37. SA Breaking News. OTIC, VTRS among premarket losers. 02/22 08:25. MT Newswires . Correction: Otonomy Shares Tumble 47% After Otividex Trial for Meniere's Disease Treatment Misses Primary Endpoint. 02/22 08:01. SA Breaking News. Otonomy sinks after Otividex fails in late-stage trial for. Otonomy Inc (NASDAQ:OTIC) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we'd rather spend our time.
A look at the shareholders of Otonomy, Inc. (NASDAQ:OTIC) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. We also tend to see lower insider ownership in companies that were previously publicly owned. Otonomy is not a large company by global standards. It has a. Otonomy Inc (. OTIC. ) HEALTH CARE: PHARMACEUTICALS. SIC: PHARMACEUTICAL PREPARATIONS. 4796 EXECUTIVE DRIVE SAN DIEGO, CA 92121. Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products. Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of MÃ. Federated Hermes Inc. boosted its holdings in shares of Otonomy by 23.5% in the 1st quarter. Federated Hermes Inc. now owns 4,856,200 shares of the biopharmaceutical company's stock valued at $12,383,000 after buying an additional 925,551 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of.
Get free option chain data for OTIC. Find Call and Put Strike Prices, Last Price, Change, Volume, and more for Otonomy Inc stock options Technical stocks chart with latest price quote for Otonomy Inc, with technical analysis, latest news, and opinions OTIC Stock Summary. OTIC's price/sales ratio is 666.59; that's higher than the P/S ratio of 98.73% of US stocks. As for revenue growth, note that OTIC's revenue has grown -64.26% over the past 12 months; that beats the revenue growth of just 4.26% of US companies in our set. Otonomy Inc's shareholder yield -- a measure of how much capital is. The big shareholder groups in Otonomy, Inc. (NASDAQ:OTIC) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership. With a market capitalization of US$128m, Otonomy is a small cap stock, so it might not be well. Search stocks using popular investment metrics to help you sort through companies from all major U.S. equity markets. Use Our Stock Screener » Otonomy Inc Vital